key: cord-0855183-clr55p6l
authors: Lawrence, Adrian; Mahan, Luke D.; Mohanka, Manish R.; Bollineni, Srinivas; Kaza, Vaidehi; La Hoz, Ricardo M.; Zhang, Song; Kershaw, Corey D.; Terada, Lance S.; Torres, Fernando; Banga, Amit
title: Predictors and outcomes of respiratory failure among lung transplant patients with COVID‐19
date: 2021-12-05
journal: Clin Transplant
DOI: 10.1111/ctr.14540
sha: a0a64eab884d8aed159da979e146c6399409d895
doc_id: 855183
cord_uid: clr55p6l

BACKGROUND: There is limited data on the predictors and outcomes of new or worsening respiratory failure among lung transplant (LT) patients with Coronavirus disease 2019 (COVID‐19). METHODS: We included all the LT patients diagnosed with COVID‐19 during a 1‐year period (March 2020 to February 2021; n = 54; median age: 60, 20–73 years; M:F 37:17). Development of new or worsening respiratory failure (ARF) was the primary outcome variable. RESULTS: The overall incidence of ARF was 48.1% (n = 26). More than 20% of patients (n = 11) needed intubation and mechanical ventilation. Body mass index > 25 Kg/m(2) (adjusted OR: 5.7, .99–32.93; P = .05) and peak D‐dimer levels > .95 mcg/ml (adjusted OR: 24.99, 1.77–353.8; P = .017) were independently associated with ARF while anticoagulation use prior to COVID‐19 was protective (adjusted OR: .024, .001–.55; P = .02). Majority patients survived the acute illness (85.2%). Pre‐infection chronic lung allograft dysfunction (CLAD) was an independent predictor of mortality (adjusted HR: 5.03, 1.14–22.25; P = .033). CONCLUSIONS: COVID‐19 is associated with significant morbidity and mortality among LT patients. Patients on chronic anticoagulation seem to enjoy favorable outcomes, while higher BMI and peak D‐dimer levels are associated with development of ARF. Pre‐infection CLAD is associated with an increased risk of death from COVID‐19.

overall risk of respiratory failure is estimated to be between 5% and 15%, with a minority of patients progressing to acute respiratory distress syndrome (ARDS), multiorgan failure (MOF), and death. 6, 7 Among patients with solid organ transplantation (SOT), the consequences of COVID-19 have generally been worse. 7, 8 While a weakened immune system may increase the risk of acquiring the infection and developing lower respiratory tract (LRT) involvement, it has been speculated that maintenance immunosuppression may protect against systemic hyper-inflammation. 9 Furthermore, the implications of COVID-19 may be variable among patients with different SOT. Specifically, patients with lung transplantation (LT) are likely more vulnerable by virtue of the allograft itself being the target of the SARS-CoV-2. 8 Apart from the usual effects related to COVID-19, LT patients may also be at risk for post-infection allograft dysfunction from the activation of alloimmune responses. 10 However, there is limited data regarding the spectrum of severity of COVID-19 among LT patients. The burden of severe disease, as reflected by the development of new or worsening respiratory failure (ARF) and impact on outcomes, is not well described.

The current study aims to address some of the gaps in the knowledge among LT patients with COVID-19. We sought to determine the frequency of severe disease as reflected by the development of ARF and elucidate the variables independently associated with ARF. Finally, we report post-acute illness outcomes and determine the predictors of post-COVID survival.

An analysis of a sub-group (n = 25) of the patients included in the current study has been analyzed and reported previously. 11 The current study's larger sample size and more robust statistical analysis aims to expand on the finding from the previous analysis and report independent predictors of outcomes.

The current study was a single-center retrospective chart review study approved by the UT Southwestern Medical Center Institutional Review Board (# STU-2020-1400). All patients with a history of single or bilateral LT who tested positive for SARS-CoV-2 on a nasopharyngeal swab were included. The swabs were collected for symptomatic patients between March 1, 2020, and February 15, 2021, and tested for the SARS-CoV-2 virus using the quantitative polymerase chain reaction (PCR) assay. This assay targets the nucleocapsid and RdRp genes of the novel Coronavirus using the Abbott Alinity m SARS-CoV-2 assay.

This test was validated by the UT Southwestern Medical Center Molecular Diagnostics Lab, and the limit of detection of the assay was 100 copies/ml.

The protocol for testing for SARS-CoV-2 was preformulated.

Patients were tested for SARS-CoV-2 if they presented with typical respiratory symptoms such as cough or dyspnea or separate constitutional complaints, including fatigue, malaise, or myalgias. Additionally, LT patients were tested according to the institutional screening protocols before admission to the non-COVID units or before any procedure during the study period. None of these screening tests were posi-tive, and no patient in the current series was diagnosed based on a preprocedure or pre-admission screening test. 

Data were described as median with range and proportions as appropriate. The primary endpoint for the study was the development of Statistical significance was considered at P < .05 (two-tailed only).

The analysis was done using SPSS statistical software (IBM Corp. 

During the study period, 54 patients with a history of LT were diag- He was confirmed to be positive for the SARS-CoV-2 virus on the nasopharyngeal swab. His chest radiograph was unremarkable, but screening CT chest revealed bilateral nodular ground-glass opacities. He was treated per the standard protocol but progressed to develop acute respiratory failure. However, he did not need ICU admission and was weaned off oxygen and discharged home on room air pandemic (March to October) and stabilized around 50% after that.

Notably, though, the proportion of patients with ARF during Decem- plasma appeared to be associated with ARF. Expectedly, the outcomes were consistently worse among patients with ARF (Table 1E) 

Compared to the general population, LT patients appear to be more vulnerable to complications from COVID-19 by virtue of pre-existing comorbidities, an immunosuppressed state, and, perhaps, the host immune response is focused on the allograft itself since the lung is the primary target of the SARS-CoV-2. Despite the advent of safe and effective vaccines, the vulnerability of LT patients remains apparent, with breakthrough infections leading to severe illness, including ARF and death. 13 The findings from the current analysis facilitate a better understanding of the mechanism for ARF among LT patients with COVID-19. More importantly, we identify useful clinical variables and laboratory biomarkers that could form the basis for prognosticating LT patients with COVID-19 and may be instructive in decision-making, such as the need for admission to the hospital or seeking a higher level of care. It appears likely that the COVID-19 pandemic will evolve into an "endemic" infection with continued, albeit attenuated and highly variable, vulnerability to severe disease among vaccinated transplant patients. In such a scenario, prognostication of patients to formulate a customized and proactive management strategy is likely to be the standard of care in the future.

The temporal trends in the COVID-19 cases appear to mimic the national trends (Figure 1 ). 14 The case curve remained largely flat Heparin (Unfractionated/low molecular weight) 25 15 †Patients in this group were on chronic anticoagulation at presentation for various indications and were therefore continued on coumadin. through the early part of the pandemic and the summer months.

Notably, the LT population at our center did not experience a summer peak proportional to that seen by the general community in the state of Texas, potentially a consequence of increased vigilance with nonpharmaceutical interventions during this earlier period. The cases started to rise during the fall, but the biggest spike was seen during and after the winter holidays, a period that contributed nearly 80% of the study group.

Interestingly, none of the typical risk factors for severe COVID-19

among the general population such as diabetes, and chronic kidney disease were associated with outcomes in the LT patients. It is indeed possible that the degree of immunosuppression by virtue of being on triple therapy trumps the negative impacts from other risk factors such as diabetes or chronic kidney disease. Furthermore, the high prevalence of most comorbidities among LT patients may also contribute to the lack of association with outcomes after COVID-19.

While the study found a high burden of ARF among LT patients with COVID-19, overall survival was generally higher than in the previously reported series (Table 2) . 8, [15] [16] [17] [18] [19] [20] [21] [22] [23] It is noteworthy that the current series was one of the longest in terms of the duration over which the patients were included which may partially explain better outcomes.

It provides an insight into the temporal trends in the outcome of the patients over the duration of the pandemic as our understanding of the disease has improved and therapeutic modalities became available. It

Place of study to stabilize in the later part of the pandemic. In addition, patients had a lower risk of readmissions (although the length of stay with primary admission was longer as remdesivir duration was increased to 10 days among patients with CT changes) and were treated earlier with pulse dose corticosteroids during the latter half of the study period. Most deaths occurred among patients infected during the last 3 months of the study (Figure 1 ), but this was largely driven by the increased number of cases seen during this time period.

During the acute illness, pulmonary parenchymal involvement was seen among a large majority of patients on the CT chest, which is consistent with previously reported findings. Surprisingly, however, the proportion of patients with parenchymal opacities, both on chest radiographs and CT chest, was statistically no different among patients with and without ARF. It is indeed possible that the ARF was driven by mechanisms other than the interstitial involvement, with or with alveolar filling, which is the usual hallmark of viral pneumonia.

Our data suggest that beyond pulmonary infiltrates, vasculopathic changes from coagulation derangements may be a significant driver for allograft dysfunction among LT patients with COVID-19. We found a strong association between peak D-dimer levels and ARF on multivariate analysis; additionally, chronic anticoagulation was protective against ARF, suggesting a possible causal relationship. The association between coagulation defects and poor outcomes among COVID-19 is well established. 24 In fact, an elevated D-dimer has been found to be an independent predictor of mortality among other populations with 29 However, the recently published findings from the REMAP-CAP trial confirm the therapeutic benefits of anticoagulation among non-critically ill COVID-19 patients. 30 These findings validate the role of therapeutic dose anticoagulation among non-critically ill LT patients, especially those with elevated D-dimer levels.

The overall survival in the current cohort appears to be better than earlier reports, perhaps reflecting a combination of improvement in the understanding of the disease, availability of pharmacotherapeutic options, and the early institution of multimodality interventions. The

French study 21 published earlier this year also reported similar outcomes. Further, the current study found pre-infection CLAD as the only independent predictor of mortality, which is consistent with findings from a multicenter US study. 22 In contrast, a German study 23 did not find an association of pre-infection CLAD with mortality, although this study had a longer follow-up beyond the acute illness from COVID- 19 . It is indeed possible that CLAD may be a better predictor of survival from acute illness by reflecting the degree of pulmonary reserve, although additional studies are needed to elucidate the true impact of CLAD on COVID-19 outcomes. The current analysis has some limitations that must be considered while interpreting these results. The study was underpowered as reflected by the wide confidence intervals for the independent predictors. The associations can be prone to confounding by unrecorded variables. We had to limit the number of covariates for the multivariate models due to the sample size, which did not permit fully adjusted associations. Specifically, the association of warfarin use with better outcomes may be related to other patient characteristics, such as their underlying pulmonary condition. Patients with restrictive lung disease were less likely to be on warfarin and had a higher likelihood of ARF. We addressed this issue by adjusting the prediction models for ARF by including patient demographics and transplant indication as covariates to adjust the associations. The study design precludes any conclusions regarding the causality of the association and must await further assessments. Finally, the mechanistic links to explain the association are speculative as prospective studies in this population are sorely lacking.

In summary, the current series provides useful information regarding the burden of ARF among LT patients with COVID-19. While survival has improved since the onset of the pandemic, COVID-19 is associated with significant morbidity among LT patients with likely worsening of the expected post-transplant survival. Patients on chronic anticoagulation seem to enjoy favorable outcomes, while LT patients with an elevated BMI and D-dimer are at risk of ARF.

Data are available on request due to privacy or other restrictions

None.

Vaidehi Kaza https://orcid.org/0000-0003-3578-6077

Amit Banga https://orcid.org/0000-0002-6932-1537

An interactive web-based dashboard to track COVID-19 in real time

transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

COVID-19 in solid organ transplant recipients: initial report from the US epicenter

COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal

Characteristics and outcomes among patients with community-acquired respiratory virus infections during the first year after lung transplantation

Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19

Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT

COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination

COVID-19 in lung transplant patients: a case series

First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study

SARS-CoV-2 infection in two patients following recent lung transplantation

COVID-19 in lung transplant recipients: a multicenter study

From the Columbia University Lung Transplant Program. COVID-19 in lung transplant recipients: a single center case series from New York City

COVID-19 in lung transplant recipients

French group of lung transplantation. COVID-19 in lung transplant recipients

COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: a comparative analysis from a multicenter study

COVID-19 in lung transplant recipients-Risk prediction and outcomes

COVID-19-associated coagulopathy: an exploration of mechanisms

Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Characteristics and outcomes among patients with early venous thromboembolic events after lung transplant

Venous thromboembolism after adult lung transplantation: a frequent event associated with lower survival

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19

Predictors and Outcomes of Respiratory Failure among Lung Transplant Patients with COVID-19